Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Formoterol (ausschl. IHP in der Wirkstärke 6 µg), ATC R03AC13 f. d. Z. 1.10.26-30.9.28 (zzgl. V.-Opt.1x12 M.)

Section 130a (8) SGB V allows health insurance companies and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures is carried out by DAK-Gesundheit in accordance with the regulations of Part 4 of the GWB. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the above-mentioned substance Formoterol (exclusively IHP in the strength 6 µg), ATC R03AC13, DAK-Gesundheit intends to conclude discount contracts for medicines with as many interested pharmaceutical companies as possible until the entry into force of new medicines discount contracts. A discount contract in accordance with the approval model for the above-mentioned substance will come into force for the first time on 01.10.2026 and will end on 30.09.2028 (plus extension option 1x12 months). It will automatically end, irrespective of this, with the entry into force of the exclusive contract.